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MaOBJECTIVES The purpose of this study was to prospectively evaluate the safety and clinical performance of the
CoreValve Evolut R transcatheter aortic valve replacement (TAVR) system (Medtronic, Inc., Minneapolis, Minnesota) in a
single-arm, multicenter pivotal study in high- or extreme-risk patients with symptomatic aortic valve stenosis.
BACKGROUND Although outcomes following TAVR are improving, challenges still exist. The repositionable 14-F
equivalent CoreValve Evolut R TAVR system was developed to mitigate some of these challenges.
METHODS Suitable patients (n¼ 60) underwent TAVRwith a 26- or 29-mmEvolut R valve. Primary safety endpoints were
mortality and stroke at 30days. Primary clinical performance endpointswere device success per theVARC-2 (ValveAcademic
Research Consortium-2) and the percent of patients with mild or less aortic regurgitation 24 h to 7 days post-procedure.
RESULTS Patients (66.7% female; mean age 82.8 6.1 years; Society of Thoracic Surgeons Score 7.0 3.7%) underwent
TAVR via the transfemoral route in 98.3%, using a 29-mm valve in 68.3% of patients. All attempts at repositioning were
successful. No death or strokewas observed up to 30days. The VARC-2 overall device success ratewas 78.6%. Paravalvular
regurgitation post TAVR was mild or less in 96.6%, moderate in 3.4%, and severe in 0% at 30 days. Major vascular
complications occurred in 8.3%, and permanent pacemaker implantation was required in 11.7% of patients.
CONCLUSIONS The repositionable 14-F equivalent Evolut R TAVR system is safe and effective at treating high-risk
symptomatic aortic stenosis patients. Repositioning was successful when required in all patients, with low rates of
moderate or severe paravalvular aortic regurgitation and low permanent pacemaker implantation. (The Medtronic
CoreValve Evolut R CE Mark Clinical Study; NCT01876420) (J Am Coll Cardiol Intv 2015;8:1359–67)
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ABBR EV I A T I ON S
AND ACRONYMS
BAV = balloon aortic
valvuloplasty
DCS = delivery catheter system
LV = left ventricle
MRS = Modiﬁed Rankin score
MSCT = multislice computer
tomography
NYHA = New York Heart
Association
PPM = patient-prosthesis
mismatch
PVL = paravalvular leak
SAVR = surgical aortic valve
replacement
STS = Society of Thoracic
Surgeons
TAV = transcatheter aortic
valve
TAVR = transcatheter aortic
valve replacement
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1360pacemaker post-TAVR (14,15), paravalvular
leak (PVL) (16,17), stroke (18,19), and
procedure-related complications (20,21) still
remain. Technological advancements, with
conformable valve frames and more accurate
valve positioning, may improve outcomes.
The Medtronic CoreValve Evolut R Sys-
tem (Medtronic, Inc., Minneapolis, Minne-
sota) (Figure 1) was designed to mitigate
some of these difﬁculties. Detailed design
characteristics have been described previ-
ously (22). In brief, this system comprises
the Evolut R valve and the EnVeo R De-
livery Catheter System (DCS) with the
InLine sheath. The trileaﬂet valve and
sealing skirt are made out of porcine peri-
cardial tissue, sutured in a supra-annular
position on a compressible and self-
expandable nitinol frame (Figure 1A). The
Enveo R DCS enables the valve to be fully
repositionable and recapturable before full
release by turning the delivery handle(Figure 1B). The built-in InLine sheath allows for the
whole system to be inserted into a patient without
the need for a separate access sheath, reducing the
overall proﬁle of the system (Figure 1C), equivalent
to the outer diameter of a 14-F sheath.
The objectives of this prospective, single-arm,
multicenter pivotal study were to evaluate the safety
and clinical performance of the CoreValve Evolut R
TAVR system in patients with severe symptomatic
aortic valve stenosis who are at high or extreme risk
for surgical aortic valve replacement (SAVR). The
30-day outcomes are presented in this paper.
METHODS
STUDY DESIGN. This prospective, single-arm, multi-
center study was conducted at 6 centers in the United
Kingdom, Australia, and New Zealand (Online
Appendix A). The study was funded by Medtronic,
and the protocol was developed in collaboration with
the study investigators.
The study was conducted in accordance with the
Declaration of Helsinki and was consistent with Good
Clinical Practice and the applicable local regulatory
requirements. Local ethics committee approval was
obtained, and signed informed consent was obtained
from each patient who met all study inclusion criteria
and had no exclusion criteria (Online Appendix B)
before enrollment and before performing any study-
related investigations.
The study methods included the following mea-
sures to minimize potential sources of bias: An external clinical event committee, comprising
a cardiologist, a cardiothoracic surgeon, and a
neurologist, adjudicated all serious adverse events
in the study.
 A data safety monitoring board provided oversight
of all safety aspects of the study.
 All sites followed a standardized protocol for
acquisition of echocardiographic endpoint data.
 An echocardiography core laboratory (Mayo Clinic,
Rochester, Minnesota) evaluated all echocardio-
grams and echocardiographic study endpoint
results.
 All study-related data were collected electroni-
cally, and independent full source data veriﬁcation
was periodically conducted at each site.
PATIENT SELECTION. All eligible patients had
symptomatic (New York Heart Association [NYHA]
functional class $II) aortic stenosis deﬁned as an
aortic valve (AV) area of <1.0 cm2 (or AV index of <0.6
cm2/m2) and a mean AV gradient >40 mm Hg or
maximal velocity of >4.0 m/s by resting echocardio-
gram. Patients with low ﬂow/low gradient aortic ste-
nosis were permitted if they had documented
dobutamine or exercise stress echocardiography
demonstrating a mean gradient >40 mm Hg or a
maximal valve velocity >4 m/s and an AV area <1.0
cm2 (or AV area index <0.6 cm2/m2).
Risk assessment was determined on the basis of a
Society of Thoracic Surgery (STS) score $8.0% or
documented heart team agreement of high or
extreme risk for SAVR due to frailty or comorbidities.
Primary clinical exclusion criteria were any
contraindication for placement of a bioprosthetic
valve, clinically signiﬁcant untreated coronary artery
disease, severe left ventricular (LV) function (ejection
fraction <20%), end-stage renal disease, liver failure,
bare-metal stent placement within 30 days or drug-
eluting stent within 6 months before assessment,
myocardial infarction within the past 30 days, severe
dementia, or any condition that would preclude
anticoagulation. Key anatomical exclusion criteria
were a pre-existing prosthetic heart valve in any po-
sition, mixed AV disease (stenosis and regurgitation),
severe mitral or tricuspid regurgitation, moderate or
severe mitral stenosis, or bicuspid or unicuspid AV.
Multislice computed tomography (MSCT) of suit-
able patients was used to analyze the aortic annulus
and peripheral vasculature to assess anatomic suit-
ability. This information assigned patients to undergo
TAVR via the transfemoral or an alternative access
route (direct aortic or subclavian artery). Two valve
sizes were available in this study (26 or 29 mm), and
valve choice was determined by the MSCT-derived
FIGURE 1 Medtronic CoreValve Evolut R System
(A) Evolut R valve compared with CoreValve. The frame height of Evolut R has been reduced by 10% and is more conformable. The skirt
has been extended at the in-ﬂow aspect (arrow). (B) EnVeo Delivery System with InLine sheath. The InLine sheath is opposed to the capsule
during delivery into the femoral artery. Once the InLine sheath is in the femoral artery, the valve is advanced “sheathless” through the iliac
artery toward the aortic valve. (C) The EnVeo Delivery System compared with the current 18-F sheath system. By advancing “sheathless,” a true
outer diameter reduction from 22-F (current) to 18-F (14-F outer diameter [OD] equivalent) will be observed. ª2015 Medtronic, Inc. Printed
with permission. CoreValve is a registered trademark of Medtronic CV Luxembourg S.a.r.l. Evolut, EnVeo, and InLine are trademarks
of Medtronic, Inc.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 0 , 2 0 1 5 Manoharan et al.
A U G U S T 2 4 , 2 0 1 5 : 1 3 5 9 – 6 7 The CoreValve Evolut R CE Study
1361annular perimeter (26 mm: 62.8 to 72.3 mm; 29 mm:
72.3 to 81.6 mm), as per the manufacturer’s in-
structions for use.
STUDY PROCEDURE. Before patient enrollment, the
study sponsor trained all investigative teams on the
study methods, procedures, and requirements. All
implanting physicians were trained on the use of the
investigational TAVR system through didactic and
simulator sessions. Throughout the study period, anynewly learned procedural techniques were dissemi-
nated to the other investigators.
The choice of performing the procedure under
general or local anesthesia was at the discretion of the
implanting team. Although the EnVeo DCS with the
InLine sheath allows for the valve to be delivered
“sheathless,” implantation using standard techniques
(pre-positioning of an 18-F access sheath) was
allowed on the basis of the manufacturer’s in-
structions for use. Once all arterial and venous
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1362accesses were achieved, intravenous unfractionated
heparin was administered to achieve a recommended
activated clotting time of $250 s.
The “sheathless” technique required distinct steps
before advancement of the TAVR system into the
patient. Once access was obtained and pre-closure
sutures deployed, a 14-F 30-cm standard sheath
was advanced into the patient. This access was used
to cross the AV, followed by positioning of a pre-
shaped stiff support wire in the LV. The manufac-
turer’s instructions for use recommended balloon
aortic valvuloplasty (BAV) before positioning of the
valve. Once BAV was completed, the 14-F sheath was
carefully removed, maintaining wire position in the
LV. The EnVeo DCS with the InLine sheath, mounted
with the Evolut R valve, was then advanced
“sheathless” into the patient and implanted at the
annulus. Following successful valve implantation,
the EnVeo DCS was removed, and while maintaining
wire position, the 14-F sheath was re-introduced.
Following this, post-TAVR hemodynamics and
angiographic and echocardiographic assessments
were completed.
During the TAVR procedure, an electrocardio-
gram (ECG) was recorded at key procedural steps
(pre-TAVR, pre-BAV, post-BAV, immediately post-
deployment, and at completion) to prospectively
assess if or when a rhythm change may have
occurred.
During valve delivery, the Evolut R can be reposi-
tioned by either resheathing or recapturing to opti-
mally place the valve. Resheathing was deﬁned as
when only part of the valve was retrieved back into
the DCS capsule, and recapture was deﬁned as when
the valve was completely retrieved back into the DCS
with the intent to re-cross the AV (if the valve fully
migrated into the ascending aorta during deploy-
ment) or, if necessary, to completely remove the
system from the patient safely. Repositioning to
achieve an implant depth between 1 and 5 mm was
recommended.
Following successful TAVR, the use of dual anti-
platelet therapy was at the discretion of the
implanting team. Generally, the best practice recom-
mendation for the CoreValve system was used, with
dual antiplatelet therapy continued for 3 months,
followed by single antiplatelet therapy for life.
Follow-up evaluation included clinical assessment,
echocardiography, and 12-lead ECG at discharge and
30 days, and is planned through 2 years post-
procedure. Transthoracic echocardiography was per-
formed pre-implant and at 24 h to 7 days after the
implant to calculate device success. In addition, car-
diac enzymes were monitored through 30 days, andcreatine kinase-MB was collected if elevation in cre-
atine kinase was detected. Modiﬁed Rankin scores
(MRS) are documented at baseline, discharge, 30
days, 6 months, and 1 year, as well as at 1 and
3 months following any stroke events.
STUDY ENDPOINTS. There were 2 primary safety
endpoints: the rate of all-cause mortality and the rate
of any stroke at 30 days. The primary clinical perfor-
mance endpoints were the device success rate, as
deﬁned by the VARC-2 (Valve Academic Research
Consortium-2) (23), at 24 h to 7 days and the per-
cent of patients with no more than mild aortic
regurgitation at the early post-procedure echocar-
diogram (24 h through 7 days).
The secondary safety endpoints were: 1) the rates
of the VARC-2 composite early safety endpoint, which
includes death, all stroke (disabling and nondis-
abling), life-threatening bleeding, acute kidney injury
at stage 2 or 3 (including renal replacement therapy),
coronary artery obstruction requiring intervention,
major vascular complication, and valve-related
dysfunction requiring repeat procedure (BAV, TAVR,
or SAVR); and 2) the individual components at
30 days. Secondary clinical performance endpoints
included the rate of successful recapture (if tried)
and valve function by Doppler echocardiography at
30 days.
STATISTICAL METHODS. The analysis cohort for this
report comprised all 60 patients implanted with the
Evolut R transcatheter aortic valve (TAV). Baseline
categorical variables are presented as percents and
continuous variables as mean  SD. Event rates are
reported as Kaplan-Meier estimates.
The clinical performance endpoints of device suc-
cess and the percent of patients with no more than
mild aortic regurgitation were summarized with
2-sided 95% exact binomial conﬁdence intervals. The
comparisons for valve hemodynamic data (mean AV
gradient and AV area) between baseline and early
post-procedure were conducted using the paired
t-test. All statistical analyses were performed using
Statistical Analysis Systems software, version 9.2
(SAS Institute, Cary, North Carolina).
RESULTS
PATIENTS. A total of 60 patients (66.7% female;
mean age 82.8  6.1 years) underwent TAVR with the
CoreValve Evolut R system at 6 centers in the United
Kingdom, Australia, and New Zealand between
October 2013 and July 2014 (Online Appendix A). The
study cohort included each implanter’s ﬁrst experi-
ence with the Evolut R System. The overall study
FIGURE 2 Study Flow and Compliance Up to 30 Days
TABLE 1 Baseline Characteristics of Patients (n ¼ 60)
Age, yrs 82.8  6.1
Female 66.7 (40)
Logistic EuroSCORE, % 20.5  12.5
Society of Thoracic Surgeons score, % 7.0  3.7
New York Heart Association functional class
II 31.7 (19)
III 60.0 (36)
IV 8.3 (5)
Society of Thoracic Surgeons factors
Diabetes 26.7 (16)
Serum creatinine >2 mg/dl 1.7 (1)
Dialysis 0.0 (0)
Chronic lung disease (COPD) 43.3 (26)
Peripheral vascular disease 16.7 (10)
Cerebrovascular disease 13.3 (8)
Previous coronary artery bypass grafting 28.3 (17)
Previous percutaneous coronary intervention 13.3 (8)
Previous myocardial infarction 13.3 (8)
Atrial ﬁbrillation/atrial ﬂutter 36.7 (22)
Other comorbidities and medical history
Severely atherosclerotic aorta 1.7 (1)
Frailty* 68.3 (41)
Abnormal chest wall anatomy 3.3 (2)
Evidence of radiation damage 1.7 (1)
Pre-existing permanent pacemaker or deﬁbrillator 11.7 (7)
Values are mean  SD or % (n). *Deﬁned as slowness, weakness, exhaustion,
wasting and malnutrition, poor endurance and inactivity, and loss of independence
as assessed by the heart team. Frailty measurements include: 5-m walking time,
handgrip strength test using a handgrip dynamometer, body mass index <20
kg/m2 and or weight loss of 5 kg/yr; serum albumin <3.5 g/dl, and cognitive
impairment or dementia.
COPD ¼ chronic obstructive pulmonary disease; EuroSCORE ¼ European System
for Cardiac Operative Risk Evaluation.
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1363compliance for the 30-day follow-up visit was 98.3%
(Figure 2).
The mean STS score and logistic EuroSCORE were
7.0  3.7% and 20.5  12.5%, respectively. The most
prevalent STS factors at baseline were chronic lung
disease in 26 (43.3%), atrial ﬁbrillation or ﬂutter in 22
(36.7%), and prior coronary artery bypass grafting
in 17 (28.3%) patients. At baseline, 68.3% of patients
had NYHA functional class III or IV symptoms, with
41 patients (68.3%) considered to be frail (Table 1).
PROCEDURAL OUTCOMES. The majority of cases
were performed under general anesthesia (63.3%),
with transfemoral being the predominant TAVR ac-
cess route (98.3%) (Table 2). The EnVeo DCS was
advanced sheathless using the InLine sheath in the
majority of cases without difﬁculty. Pre-dilation of
the native AV was performed in 96.7% of cases, and a
20-mm balloon was used in 60.3% of cases. The
Evolut R TAVR system was advanced to the native AV
annulus in all patients without difﬁculty.
The 29-mm valve was implanted in 68.3% of
patients, and post-implant dilation was performed
in 21.7% of cases. Valve repositioning was success-
fully performed 22 times in 15 patients by either
resheathing or recapturing to optimize valve position
(Table 2). There were no instances in which the valve
needed to be completely retrieved, and there was no
valve-related dysfunction requiring a repeat proce-
dure. One patient required a second Evolut R valve
implantation due to the ﬁrst valve being deployed
supra-annularly, causing marginal aortic migration of
the valve upon full release and resulting in severe
PVL. This patient was discharged without com-
plication, with a 30-day echocardiogram showing
mild PVL.
CLINICAL OUTCOMES. There was no death or stroke
observed up to 30 days (Table 3). Symptom relief
post-TAVR was observed, with 76.3% of patients
improving by at least 1 NYHA functional class and
39.0% improving by at least 2 NYHA functional clas-
ses from baseline to 30 days. No patient had coronary
occlusion, annulus rupture, or ventricular perforation
during TAVR.
Major vascular complication was observed in
5 patients (8.3%). Two patients required access
intervention following TAVR: 1 patient experienced a
dissection of the right common femoral artery,
treated successfully with angioplasty with no further
sequelae, and the other had a failed percutaneous
closure device leading to bleeding and hematoma,
treated with blood products and left femoral artery
stenting. Access groin hematoma was noted in the
other 3 patients, with 2 requiring blood products.
TABLE 2 Procedural Outcomes Through 30 Days (n ¼ 60)
Procedure time, min 83.7  26.7
Total ﬂuoroscopy time, min (n ¼ 58) 24.1  9.3
General anesthesia 63.3 (38)
Access
Iliofemoral 98.3 (59)
Direct aortic 1.7 (1)
Pre-TAVR balloon valvuloplasty 96.7 (58)
Successful valve repositioning, if attempted (n ¼ 15)* 100 (22/22)
Valve resheathing, n 10
Valve recapture, n 12
Valve size implanted
26-mm 31.7 (19)
29-mm 68.3 (41)
Post-TAVR balloon valvuloplasty 21.7 (13)
New permanent pacemaker implantation† 11.7 (7)
Implant depth, mm‡
Noncoronary sinus 3.9  3.0
Left coronary sinus 4.9  3.0
Length of stay, days 5.0  2.5
Values are mean  SD or % (n). *22 attempts in 15 patients. †Patients with a
pacemaker or implantable cardioverter-deﬁbrillator at baseline are included.
‡Center-reported measurements.
TAVR ¼ transcatheter aortic valve replacement.
TABLE 3 Clinical Outcomes at 30 Days (n ¼ 60)
All-cause mortality 0.0 (0)
All stroke 0.0 (0)
Life-threatening or disabling bleeding 5.0 (3)
Acute kidney injury: stage 2 or 3 1.7 (1)
Coronary artery obstruction 0.0 (0)
Annular rupture/dissection 0.0 (0)
Left ventricular perforation 0.0 (0)
Major vascular complication 8.3 (5)
Valve-related dysfunction requiring repeat procedure 0.0 (0)
VARC-2 composite safety endpoint 13.3 (8)
Values are Kaplan-Meier rates (n).
VARC-2 ¼ Valve Academic Research Consortium-2.
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1364Life-threatening or disabling bleedingwas observed
in 3 patients, occurring at the access site, permanent
pacemaker site, or induced by the endotracheal tube.
At 30 days, a new permanent pacemaker implan-
tation was required in 11.7% of patients. Six patients
had third-degree atrioventricular block, and 1 had
second-degree atrioventricular block post-procedure.
All permanent pacemaker implants occurred between
1 and 5 days post-TAVR. Pre-procedure ECG abnor-
malities were present in 4 patients: 2 had ﬁrst-degree
atrioventricular block, 1 had right bundle branch
block (RBBB), and 1 had both RBBB and ﬁrst-degree
atrioventricular block. When the depth of implant
was reviewed, the average depth for those who
received a pacemaker (left coronary cusp [LCS] 9.4 
3.1 mm; noncoronary cusp [NCS] 8.1  3.5 mm) was
signiﬁcantly deeper than that of patients who did not
receive a new pacemaker (LCS 4.3  2.5 mm; NCS
3.3  2.5 mm; p < 0.0001 for both comparisons).
The VARC-2 overall device success rate was 78.6%
post-procedure (Table 4). In 5 patients, the effective
oriﬁce area (EOA) could not be determined to calcu-
late the patient-prosthesis mismatch (PPM).
ECHOCARDIOGRAPHIC OUTCOMES. The Evolut R TAV
effectively reduced the mean AV gradient from
49.1  13.0 mm Hg at baseline to 9.2  3.9 mm Hg early
post-procedure (p < 0.0001). The AV area was also
signiﬁcantly improved from 0.6  0.2 cm2 at baseline
to 1.9  0.5 cm2 early post-procedure (p < 0.0001).Figure 3 shows valve hemodynamics through 30 days.
Mild or less PVL occurred post-TAVR in 96.6% of pa-
tients; 2 patients had moderate and none had severe
PVL at 30 days (Figure 4).
DISCUSSIONS
This prospective, multicenter, ﬁrst-in-man study has
demonstrated that the resheathable Medtronic Cor-
eValve Evolut R TAVR system is safe, with good
clinical performance at treating high-risk symptom-
atic patients with severe aortic stenosis. No death or
stroke were observed up to 30 days, and the overall
VARC-2–deﬁned device success rate at 24 h to 7 days
post-procedure was 78.6%, with 93.2% of patients
having mild or less PVL. The PVL improved at
30 days, with 96.6% having mild or less, 3.4% having
moderate, and none having severe PVL.
Although study design, patient selection, and TAVR
experience may differ, the 30-day mortality and
stroke rates observed in this study compare favor-
ably to those reported in other studies using ﬁrst-
generation (10,11,24,25) or next-generation (26–29)
devices. Despite patients in this study having an STS
score of 7.0  3.7%, the absence of primary clinical
events at 30 days may in part be due to the use of
MSCT (for sizing and assessment of coronary ostia),
careful adherence to best practices learned from
global use of the Medtronic CoreValve device, appro-
priate patient selection, the self-expanding nature of
the TAVR system, and the resheathable feature of the
Evolut R system.
Stroke, coronary occlusion, annular rupture, and
LV perforation during TAVR signiﬁcantly affects pa-
tient outcomes post-TAVR. The low stroke rate
observed in this study is consistent with that reported
(0% to 4%) from other studies (26–29). Female sex,
use of the balloon-expandable TAVR system, previ-
ous bioprosthetic AV, and low-lying coronary ostia
FIGURE 3 Mean Echocardiographic Hemodynamic Measurements
Error bars represent SDs.
FIGURE 4 Post-Procedure Echocardiographic Paravalvular Leak Assessments
TABLE 4 VARC-2–Deﬁned Device Success (n ¼ 60)
Absence of procedural mortality 100 (60/60)
Correct position of 1 valve in the proper location 98.3 (59/60)
Mean gradient <20 mm Hg or peak velocity <3 m/s 98.3 (59/60)
Absence of moderate or severe regurgitation 93.3 (56/60)
Absence of patient-prosthesis mismatch* 83.6 (46/55)
Overall device success 78.6 (44/56)
Values are % (n/N). *The effective oriﬁce area could not be determined in
5 patients to calculate patient-prosthesis mismatch.
VARC-2 ¼ Valve Academic Research Consortium-2.
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1365are risk factors for coronary occlusion (30). Severe
annular calciﬁcation, the use of a balloon-expandable
TAVR system, and aggressive post-dilation are asso-
ciated with annular rupture (31,32). None of these
complications were observed in this study.
Device success, as intended by VARC-2, requires a
composite of: 1) absence of procedural mortality;
2) correct position of a single prosthetic valve; and
3) intended performance of the prosthetic valve (no
PPM mean valve gradient <20 mm Hg or peak
velocity <3 m/s, and no moderate or severe prosthetic
regurgitation). Failure to meet any 1 of these 3 pa-
rameters will categorize the device a failure. The de-
vice success rate for this study was lower than
expected (Table 4) and was driven predominantly by
the presence of calculated PPM in 9 patients. The
challenges with calculating PPM are recognized,
especially when transthoracic rather than trans-
esophageal echocardiography is used to measure LV
outﬂow tract diameter. Furthermore, these data were
not available in 5 patients, further affecting the de-
vice success rate. Importantly, the mean EOA at 24 h
to 7 days and at 30 days was good (1.9  0.5 cm2), with
low mean gradients of 9.2  3.9 mm Hg and 8.1  3.3
mm Hg, respectively.
REPOSITIONABILITY AND SAFETY. Repositioning with
the Evolut R was performed 22 times in 15 patients
safely and without difﬁculty to optimize ﬁnal valve
implant position. Repositioning in these 15 patients
enabled an average ﬁnal implant depth of 5.9  3.4
mm for NCS and 6.3  4.1 mm for LCS. The ability to
resheath and reposition in turn contributed to the
overall good clinical outcomes, with no death or
stroke, low to moderate PVL rates, and low perma-
nent pacing rates observed in this study.
The novel distal portion of the capsule (containing
the crimped valve [Figure 1B]) expands to facilitate
valve resheathing and recapturing of a partially
released Evolut R valve, which reduces friction and
mechanical stress encountered during repositioning,
thereby reducing agitation of friable native valvetissue and potentially contributing to the absence of
clinical stroke observed.
PERMANENT PACEMAKER IMPLANTATION. The rate of
permanent pacemaker implantation was 11.7% in our
study. The rate of permanent pacemaker implantation
post-TAVR with the CoreValve device ranges between
11% and 40% (33,34) and for the Edwards SAPIEN
between 3% and 8% (35). More recently, the mul-
ticenter ADVANCE II (CoreValve Prospective Inter-
national Post-Market Advance II Study) study,
investigating the effect of best practice on rhythm
disturbances with the CoreValve device, reported
pacing rates of 13.3% (36). Similar low rates of pacing
were also observed with other new TAVR devices
(27–29); however, the Lotus system reported a pacing
PERSPECTIVES
WHAT IS KNOWN? High-risk or inoperable patients
with symptomatic severe aortic stenosis are increas-
ingly treated by TAVR; however, challenges such as
death, stroke, paravalvular leak, and need for per-
manent pacing exist.
WHAT IS NEW? TAVR with the 14-F–equivalent,
repositionable Medtronic Evolut R system results in
reduced event rates.
WHAT IS NEXT? Larger studies are required to
evaluate and conﬁrm the ﬁndings of this small pivotal
study.
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1366rate of 28.6% (26). Although the cause ismultifactorial,
pre-existing RBBB (37), ﬁnal device depth, and over-
sizing are suggested triggers.
The lower pacing rate in this study could be attrib-
uted to: 1) the redesigned delivery system (with
resheath and recapture capability) enabling more
accurate positioning; and 2) the modiﬁed, more
conformable nitinol frame design resulting in a
more uniform outward force and reduced stiffness at
the inﬂow portion of the valve, thus potentially
reducing trauma to the conduction system as com-
pared with the CoreValve system. Of the 7 patients
who received a permanent pacemaker through
30 days, 4 had pre-existing conduction abnormal-
ities and all had signiﬁcantly lower ﬁnal deployment
depth as compared with the study average.
PARAVALVULAR LEAK. Moderate to severe PVL
post-TAVR is associated with a poor prognosis
(38,39). Potential causes include suboptimal posi-
tioning, undersizing, and eccentric calciﬁcation. A
more conformable frame, MSCT-based sizing, and
repositionability may mitigate some of these chal-
lenges, as observed in this study. The observed rates
for PVL mild or less (96.6%) and moderate (3.4%) with
the Evolut R compare favorably to the CoreValve
(mild or less: 91%; moderate to severe: 9%) (11), and
appear similar to SAPIEN S3 (mild or less: 96.6%;
moderate: 3.4%) at 30 days (29).
HEMODYNAMIC PERFORMANCE. Aortic valve pres-
sure gradient and valve area were signiﬁcantly
improved following Evolut R TAV implantation
(Figure 3). Absence of PPM at the early post-implant
echocardiogram (in 55 evaluable patients) was 83.6%.
Despite the challenges and inconsistency with
deriving these data, they appear to be better than that
reported in the Reprise II (60.7%) (26) or the PARTNER
(40% to 56%) (40) studies. This may, in part, be due to
the supra-annular function of the Evolut R valve.
Furthermore, the mean gradient and EOA at 30 days
for the Evolut R were equivalent to those reported
for the CoreValve bioprosthesis in the CoreValve US
Extreme Risk (8.7  4.2 mm Hg and 1.86  0.56 cm2)
(25) and High Risk (8.9  3.9 mm Hg and 1.95 
0.56 cm2) (11) studies.
VASCULAR COMPLICATIONS. The rates of major
vascular complications (MVC) (8.3%) and life-
threatening bleeding events (5.0%) are consistent
with rates reported for the CoreValve system. The
CoreValve Extreme Risk (25) and High Risk (11)
studies reported MVC rates of 8.2% and 5.9%,
respectively, and life-threatening bleeding events of
12.7% and 13.6%, respectively. Patients with MVC in
our study had a slightly higher body mass index whencompared with those who did not (28.2  5.0 kg/m2
vs. 26.8  4.8 kg/m2; p ¼ 0.53), which may have
contributed to the access-related events.
STUDY LIMITATIONS. This was a ﬁrst-in-man study
of the use of the Evolut R TAV in patients at high or
prohibitive risk of SAVR. The study size was relatively
small, with a short (30-day) follow-up. Longer-term
follow-up to 2 years is planned. Although all patients
had MRS assessments pre- and post-TAVR, formal
neurological assessments were not performed unless
a change in MRS was observed. The absence of clin-
ical neurological events may also be in part due to the
small study numbers. Larger studies are required to
further evaluate clinical outcomes.
CONCLUSIONS
This study conﬁrms the clinical safety and perfor-
mance of the next-generation Evolut R repositionable
TAVR system in treating high-risk or surgically inop-
erable symptomatic aortic stenosis patients. Future
studies will further help to validate the favorable
outcomes observed in this study.
ACKNOWLEDGMENTS The authors would like to
thank Jane Moore, MS, ELS, an employee of the
sponsor who, under the direction of the authors,
drafted the methods and results sections and pre-
pared all tables and ﬁgures to meet journal re-
quirements. The authors would also like to thank the
clinical study management team of Charles Boldt,
MS, and Kelly Hendrickson, MS.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Ganesh Manoharan, Cardiology Department, Royal Vic-
toria Hospital, 274 Grosvenor Road, Belfast BT12 6BA,
United Kingdom. E-mail: gmanoharan@msn.com.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 0 , 2 0 1 5 Manoharan et al.
A U G U S T 2 4 , 2 0 1 5 : 1 3 5 9 – 6 7 The CoreValve Evolut R CE Study
1367RE F E RENCE S1. Lindroos M, Kupari M, Heikkila J, et al. Preva-
lence of aortic valve abnormalities in the elderly:
an echocardiographic study of a random popula-
tion sample. J Am Coll Cardiol 1993;2:1220–5.
2. Iung B, BaronG, Butchart EG, et al. A prospective
survey of patients with valvular heart disease in
Europe: the Euro Heart Survey on valvular heart
disease. Eur Heart J 2003;24:1231–43.
3. Ross J Jr., Braunwald E. Aortic stenosis. Circu-
lation 1968;38 Suppl:61–7.
4. Rosenhek R, Zilberszac R, Schemper M, et al.
Natural history of very severe aortic stenosis.
Circulation 2010;121:151–6.
5. Clark MA, Arnold SV, Duhay FG, et al. Five-year
clinical and economic outcomes among patients
with medically managed severe aortic stenosis:
results from a Medicare claims analysis. Circ Car-
diovasc Qual Outcomes 2012;5:697–704.
6. Nishimura RA, Otto CM, Bonow RO, et al. 2014
AHA/ACC guideline for the management of pa-
tients with valvular heart disease: a report of the
American College of Cardiology/American Heart
Association Task Force on Practice Guidelines.
J Am Coll Cardiol 2014;63:e57–185.
7. Vahanian A, Alﬁeri O, Andreotti F, et al. Guide-
lines on the management of valvular heart disease
(version 2012). Eur Heart J 2012;33:2451–96.
8. Iung B, Cachier A, Baron G, et al. Decision-
making in elderly patients with severe aortic
stenosis: why are so many denied surgery? Eur
Heart J 2005;26:2714–20.
9. Bach DS, Siao D, Girard SE, et al. Evaluation of
patientswithseveresymptomaticaortic stenosiswho
do not undergo aortic valve replacement: the po-
tential role of subjectively overestimated operative
risk. Circ Cardiovasc Qual Outcomes 2009;2:533–9.
10. Smith C, Leon M, Mack M, et al., for the
PARTNER Trial Investigators. Transcatheter versus
surgical aortic valve replacement in high-risk pa-
tients. N Engl J Med 2011;364:2187–98.
11. Adams DH, Popma JJ, Reardon MJ, et al.
Transcatheter aortic-valve replacement with a
self-expanding prosthesis. N Engl J Med 2014;
370:1790–8.
12. Tchetche D, Dumonteil N, Sauguet A, et al.
Thirty-day outcome and vascular complications
after transarterial aortic valve implantation using
both Edwards Sapien and Medtronic CoreValve
bioprosthesis in a mixed population. Euro-
Intervention 2010;5:659–65.
13. Van Mieghem NM, Nuis RJ, Piazza N, et al.
Vascular complications with transcatheter aortic
valve implantation using the 18 Fr Medtronic
CoreValve System: the Rotterdam experience.
EuroIntervention 2010;5:673–9.
14. Fraccaro CBG, Tatantini G, Gasparetto V, et al.
Incidence, predictors, and outcome of conduction
disorders after transcatheter self-expanding aortic
valve implantation. Am J Cardiol 2011;107:747–54.
15. van der Boon RM, Nuis RJ, Van Mieghem NM,
et al. New conduction abnormalities after TAVI—
frequencies and causes. Nat Rev Cardiol 2012;9:
454–63.16. Kodali S, Williams M, Smith C, et al., for the
PARTNER Trial Investigators. Two-year outcomes
after transcatheter or surgical aortic-valve
replacement. N Engl J Med 2011;366:1686–95.
17. Sherif M, Abdel-Wahab M, Stocker B, et al.
Anatomic and procedural predictors of para-
valvular aortic regurgitation after implantation of
the Medtronic CoreValve bioprosthesis. J Am Coll
Cardiol 2010;56:1623–9.
18. Eggebrecht H, Schmererund A, Voigtlander T,
et al. Risk of stroke after transcatheter aortic
valve implantation (TAVI): a meta-analysis of
10,037 published patients. EuroIntervention 2012;
8:129–38.
19. Nuis RJ, Van Mieghem N, Schultz C, et al.
Frequency and causes of stroke during or after
transcatheter aortic valve implantation. Am J
Cardiol 2012;109:1637–43.
20. Lange R, Bleiziffer S, Piazza N, et al. Incidence
and treatment of procedural cardiovascular com-
plications associated with trans-arterial and trans-
apical interventional aortic valve implantation in
412 consecutive patients. Eur J Cardiothorac Surg
2011;40:1105–13.
21. Ribeiro HB, Nombela-Franco L, Urena M, et al.
Coronary obstruction following transcatheter
aortic valve implantation: a systematic review.
J Am Coll Cardiol Intv 2013;6:452–61.
22. Sinning JM, Werner N, Nickenig G, et al.
Medtronic CoreValve Evolut R with Enveo R.
EuroIntervention 2013;9:s95–6.
23. Kappetein AP, Head S, Généreux P, et al.
Updated standardized endpoint deﬁnitions for
transcatheter aortic valve implantation: the Valve
Academic Research Consortium-2 consensus
document. J Am Coll Cardiol 2012;60:1438–54.
24. Leon M, Smith C, Mack M, et al., for the
PARTNER Trial Investigators. Transcatheter aortic
valve implantation for aortic stenosis in patients
who cannot undergo surgery. N Engl J Med 2010;
363:1597–607.
25. Popma JJ, Adams DH, Reardon MJ, et al.
Transcatheter aortic valve replacement using a
self-expanding bioprosthesis in patients with se-
vere aortic stenosis at extreme risk for surgery.
J Am Coll Cardiol 2014;63:1972–81.
26. Meredith IT, Walters DL, Dumonteil N, et al.
Transcatheter aortic valve replacement for severe
symptomatic aortic stenosis using a repositionable
valve system: 30-day primary endpoint results
from the REPRISE II study. J Am Coll Cardiol 2014;
64:1339–48.
27. Manoharan G. Multicentre clinical study eval-
uating a novel resheathable self-expanding
transcatheter aortic valve system. Paper pre-
sented at: Transcatheter Therapeutics; September
13, 2014; Washington, DC.
28. Schofer J, Colombo A, Klugmann S, et al.
Prospective multicenter evaluation of the Direct
Flow Medical transcatheter aortic valve. J Am Coll
Cardiol 2014;63:763–8.
29. Webb J, Gerosa G, Lefèvre T, et al. Multi-
center evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll
Cardiol 2014;64:2235–43.
30. RibeiroHB,Webb JG,MakkarRR, et al. Predictive
factors, management, and clinical outcomes of cor-
onary obstruction following transcatheter aortic
valve implantation: insights from a largemulticenter
registry. J Am Coll Cardiol 2013;62:1552–62.
31. Holmes DR Jr., Mack MJ, Kaul S, et al. 2012
ACCF/AATS/SCAI/STS expert consensus document
on transcatheter aortic valve replacement. J Am
Coll Cardiol 2012;59:1200–54.
32. Pasic M, Unbehaun A, Dreysse S, et al. Rupture
of the device landing zone during transcatheter
aortic valve implantation: a life-threatening but
treatable complication. Circ Cardiovasc Interv
2012;5:424–32.
33. Tchetche D, Modine T, Farah B, et al. Update
on the need for a permanent pacemaker after
transcatheter aortic valve implantation using the
CoreValve Accutrak system. EuroIntervention
2012;8:556–62.
34. Tzikas A, van Dalen BM, VanMieghemNM, et al.
Frequency of conduction abnormalities after trans-
catheter aortic valve implantation with the
Medtronic-CoreValve and the effect on left ventric-
ular ejection fraction. Am J Cardiol 2011;107:285–9.
35. Webb JG, Wood DA. Current status of trans-
catheter aortic valve replacement. J Am Coll Car-
diol 2012;60:483–92.
36. Petronio AS, Zucchelli G, Kovac J, de Jaegere P.
ADVANCE II: best practices investigation in
patients undergoing transcatheter aortic valve
implantation with a self-expanding valve. Paper
presented at: Annual Meeting of the EuroPCR; May
22, 2014; Paris, France.
37. Piazza N, Nuis R, Tzikas A, et al. Persistent con-
duction abnormalities and requirements for pace-
making six months after transcatheter aortic valve
implantation. EuroIntervention 2010;6:475–503.
38. Sinning JM, Hammerstingl C, Vasa-Nicotera M,
et al. Aortic regurgitation index predicts severity or
peri-prosthetic regurgitation and predicts outcome
in patients after transcatheter aortic valve implan-
tation. J Am Coll Cardiol 2012;59:1134–41.
39. Takagi K, Latib A, Al-Lamee R, et al. Predictors
of moderate-to-severe paravalvular regurgitation
immediately after CoreValve implantation and the
impact of postdilation. Catheter Cardiovasc Interv
2011;78:432–43.
40. Pibarot P, Weissman N, Stewart W, et al.
Incidence and sequelae of prosthesis-patient
mismatch in transcatheter versus surgical valve
replacement in high-risk patients with severe
aortic stenosis: a PARTNER Trial Cohort-A analysis.
J Am Coll Cardiol 2014;64:1323–34.
KEY WORDS aortic valve stenosis,
self-expanding heart valve, transcatheter
aortic valve replacement
APPENDIX For additional study information
and subject selection criteria, please see the
online version of this article.
